Last reviewed · How we verify
MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
1 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| APOKYN | APOKYN | marketed | Dopaminergic Agonist | D(2) dopamine receptor | Neuroscience | |
| apomorphine infusion | apomorphine infusion | phase 3 |
Therapeutic area mix
- Neuroscience · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Pfizer · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals:
- MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals pipeline updates — RSS
- MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals pipeline updates — Atom
- MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals pipeline updates — JSON
Cite this brief
Drug Landscape (2026). MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/mdd-us-operations-llc-a-subsidiary-of-supernus-pharmaceuticals. Accessed 2026-05-17.